<DOC>
	<DOC>NCT02698384</DOC>
	<brief_summary>The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to describe the modalities and the global effectiveness of alternative strategies.</brief_summary>
	<brief_title>Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Male or female aged 18 years or more, suffering from acromegaly Treatment na√Øve or treated subject (whatever the previous treatments except Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. Requiring a treatment with Somatostatin analog (SSA) Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within the previous 12 weeks (postsurgery MRI for operated subjects) In whom the physician has already decided to initiate a treatment with Lanreotide 120mg as a monotherapy Subject previously/currently treated with Lanreotide 120mg History of radiotherapy for acromegaly Subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists Active neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>